Treating dendritic cells with the CD137 ligand (4-1BB) enhances the inflammatory response of neighboring T cells, enhances T cell bioenergetics, and results in greater lysis of target infected cells; in the cases of hepatitis and Epstein–Barr-infected HepG2 cells, viruses associated with cancer [80]. This evidence concerns the gene TNFRSF9 and cancer.